Outcome of Patients Treated for Relapsed or Refractory Acute Lymphoblastic Leukemia: A Therapeutic Advances in Childhood Leukemia Consortium Study
Authors:
- Lingyun JiLJLingyun Ji
- Phillip BarnettePBPhillip Barnette
- Bruce BostromBBBruce Bostrom
- Raymond HutchinsonRHRaymond Hutchinson
- Elizabeth RaetzERElizabeth Raetz
- Nita L. SeibelNSNita L. Seibel
- Clare J. TwistCTClare J. Twist
- Elena EckrothEEElena Eckroth
- Richard SpostoRSRichard Sposto
- Paul S. GaynonPGPaul S. Gaynon
- Mignon L. LohMLMignon L. Loh
- 1 February 2010
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (4) , 648-654
Abstract
Purpose: Despite improvements in treatment, approximately 20% of patients with acute lymphoblastic leukemia (ALL) experience relapse and do poorly. The Therapeutic Advances in Childhood Leukemia (TACL) Consortium was assembled to assess novel drugs for children with resistant leukemia. We hypothesize that novel agents and combinations that fail to improve baseline complete remission rates in comparable populations are unlikely to contribute to better outcomes and should be abandoned. We sought to define response rates and disease-free survival (DFS) rates in patients treated at TACL institutions, which could serve as a comparator for future studies. Patients and Methods: We performed a retrospective cohort review of patients with relapsed and refractory ALL previously treated at TACL institutions between the years of 1995 and 2004. Data regarding initial and relapsed disease characteristics, disease response, and survival were collected and compared with those of published reports. Results: Complete remission (CR) rates (mean ± SE) were 83% ± 4% for early first marrow relapse, 93% ± 3% for late first marrow relapse, 44% ± 5% for second marrow relapse, and 27% ± 6% for third marrow relapse. Five-year DFS rates in CR2 and CR3 were 27% ± 4% and 15% ± 7% respectively. Conclusion: We generally confirm a 40% CR rate for second and subsequent relapse, but our remission rate for early first relapse seems better than that reported in the literature (83% v approximately 70%). Our data may allow useful modeling of an expected remission rate for any population of patients who experience relapse.Keywords
This publication has 27 references indexed in Scilit:
- Long‐term outcome of initially homogenously treated and relapsed childhood acute lymphoblastic leukaemia in Austria – A population‐based report of the Austrian Berlin‐Frankfurt‐Münster (BFM) Study GroupBritish Journal of Haematology, 2009
- Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group studyLeukemia, 2008
- Reinduction Platform for Children With First Marrow Relapse of Acute Lymphoblastic Leukemia: A Children's Oncology Group StudyJournal of Clinical Oncology, 2008
- Chemoimmunotherapy Reinduction With Epratuzumab in Children With Acute Lymphoblastic Leukemia in Marrow Relapse: A Children's Oncology Group Pilot StudyJournal of Clinical Oncology, 2008
- Outcome After Relapse Among Children With Standard-Risk Acute Lymphoblastic Leukemia: Children's Oncology Group Study CCG-1952Journal of Clinical Oncology, 2007
- Pathways Through Relapses and Deaths of Children With Acute Lymphoblastic Leukemia: Role of Allogeneic Stem-Cell Transplantation in Nordic DataJournal of Clinical Oncology, 2006
- Outcome after first relapse in childhood acute lymphoblastic leukaemia – lessons from the United Kingdom R2 trialBritish Journal of Haematology, 2005
- RELAPSED LYMPHOBLASTIC LEUKAEMIA IN CHILDREN: A CONTINUING CHALLENGEBritish Journal of Haematology, 1998
- Idarubicin and Cytosine Arabinoside Reinduction Therapy for Children with Multiple Recurrent or Refractory Acute Lymphoblastic Leukemia: A Pediatric Oncology Group StudyJournal of Pediatric Hematology/Oncology, 1997
- Ifosfamide and Etoposide in Recurrent Childhood Acute Lymphoblastic LeukemiaJournal of Pediatric Hematology/Oncology, 1995